Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 3/20 | 0.51 |
| ▸ | MMP1 | P03956 | 3/20 | 0.51 |
| ▸ | GRK2 | P25098 | 1/20 | 0.49 |
| ▸ | IGF1R | P08069 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12259812 | 0.93 | MMP13 (0.58) | MMP13MMP1NPSR1HTTHSD11B1 | |
| SCHEMBL12237259 | 0.87 | ALDH1A1 (0.54) | MMP13MMP1EGFRNPSR1HTT | |
| SCHEMBL28410587 | 0.87 | ALDH1A1 (0.54) | MMP13MMP1EGFRNPSR1HTT | |
| SCHEMBL28410589 | 0.87 | ALDH1A1 (0.54) | MMP13MMP1EGFRNPSR1HTT | |
| SCHEMBL12259813 | 0.86 | GAA (0.52) | MMP13MMP1EGFRERBB2NPSR1 | |
| SCHEMBL28397210 | 0.85 | HSD11B1 (0.61) | MMP13MMP1EGFRERBB2NPSR1 | |
| SCHEMBL28748804 | 0.85 | HSD11B1 (0.61) | MMP13MMP1EGFRERBB2NPSR1 | |
| SCHEMBL28397208 | 0.85 | HSD11B1 (0.61) | MMP13MMP1EGFRERBB2NPSR1 | |
| SCHEMBL12237256 | 0.82 | KMT2A (0.49) | MMP13MMP1POLBNPSR1ALDH1A1 | |
| SCHEMBL12237257 | 0.81 | HSD11B1 (0.48) | GRK2IGF1REGFRERBB2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2306986-B1 | PRODRUGS AND DRUG-MACROMOLECULE CONJUGATES HAVING CONTROLLED DRUG RELEASE RATES | PROLYNX LLC (US) | 2018-03-21 | — | — | EP | disclosed |
| US-9387254-B2 | Prodrugs and drug-macromolecule conjugates having controlled drug release rates | PROLYNX LLC (US) | 2016-07-12 | — | — | US | disclosed |
| US-9387254-B2 | Prodrugs and drug-macromolecule conjugates having controlled drug release rates | PROLYNX LLC (US) | 2016-07-12 | — | — | US | disclosed |
| US-20140296476-A1 | PRODRUGS AND DRUG-MACROMOLECULE CONJUGATES HAVING CONTROLLED DRUG RELEASE RATES | PROLYNX LLC | 2014-10-02 | — | — | US | disclosed |
| US-20140296476-A1 | PRODRUGS AND DRUG-MACROMOLECULE CONJUGATES HAVING CONTROLLED DRUG RELEASE RATES | PROLYNX LLC | 2014-10-02 | — | — | US | disclosed |
| US-8680315-B2 | Prodrugs and drug-macromolecule conjugates having controlled drug release rates | PROLYNX, LLC (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680315-B2 | Prodrugs and drug-macromolecule conjugates having controlled drug release rates | PROLYNX, LLC (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110263502-A1 | PRODRUGS AND DRUG-MACROMOLECULE CONJUGATES HAVING CONTROLLED DRUG RELEASE RATES | PROLYNX, LLC | 2011-10-27 | — | — | US | disclosed |
| US-20110263502-A1 | PRODRUGS AND DRUG-MACROMOLECULE CONJUGATES HAVING CONTROLLED DRUG RELEASE RATES | PROLYNX, LLC | 2011-10-27 | — | — | US | disclosed |
| WO-2009158668-A1 | PRODRUGS AND DRUG-MACROMOLECULE CONJUGATES HAVING CONTROLLED DRUG RELEASE RATES | PROLYNX LLC (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296476-A1 | PRODRUGS AND DRUG-MACROMOLECULE CONJUGATES HAVING CONTROLLED DRUG RELEASE RATES | ABCB1, ABCB11, DNPEP | MMP13 102/4885MMP1 83/4885GRK2 4204/4885 |
| US-20110263502-A1 | PRODRUGS AND DRUG-MACROMOLECULE CONJUGATES HAVING CONTROLLED DRUG RELEASE RATES | ABCB1, ABCB11, DNPEP | MMP13 102/4885MMP1 83/4885GRK2 4204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.